Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06489847 · ClinicalTrials.gov registry record
An Objective Assessment Tool for Evaluating Functioning in Older Adults
A clinical trial of Alzheimer Disease, sponsored by Stanford University.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06489847: Recruiting study of Alzheimer Disease, sponsored by Stanford University.
NCT06489847 is a study of Alzheimer Disease that is actively recruiting participants, run by Stanford University. The registered enrollment target is 30 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06489847, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The Investigators are seeking your consent to participate in research investigating the development of a mobile application that enhances physical and cognitive assessments. This is in response to the growing significance of the Short Physical Performance Battery (SPPB) in Alzheimer's Disease and Related Dementias (AD/ADRD) research. The SPPB has proven its value in evaluating lower extremity function and mobility in older adults, providing predictive insights into declines in daily living activities, falls, hospitalization, disability, and mortality. Recognizing the need for accessible and automated assessment tools, this project endeavors to design a mobile app with multi-fold functionality. The final version will guide users through SPPB tests, offer real-time performance scoring, and facilitate frequent, objective, and accurate physical and cognitive assessments. This is particularly critical for monitoring the progression of ADRD, identifying subtle physical changes indicative of cognitive decline, and enabling timely interventions tailored to patients' evolving needs. Our goal is to collect video data from 20 to 30 participants 18+ years of age who are considered healthy with no severe mobility issues to perform the SPPB. The video data will be used to develop a prototype of the SPPB application and validate testing in the lab. The video recording will be automatically encrypted and securely uploaded to Stanford privacy protected computer servers to test and refine the application results.
Primary Outcome
Novel Biomarker Types: In this study, we propose to leverage video data to develop an automated analysis of the SPPB clinical tests, the same way that MRI data can automatically be analyzed. This will remove the need for subjective evaluation and lead to universally acceptable disease (digital) biomarkers from the video data, helping the clinicians. The video-based biomarkers will serve as quantifiable identifiers singling out specific subtype(s). Such digital biomarkers \[9-19,21\] and especial
Conditions Studied
Interventions
- DIAGNOSTIC_TEST SPPB++ Application
Study Locations (1)
California
- Clinical Excellence Research Center - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2028-10-30 |
What NCT06489847 shows while recruiting
NCT06489847 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which SPPB++ Application is the first listed.
NCT06489847 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06489847 about?
NCT06489847 is a clinical study titled "An Objective Assessment Tool for Evaluating Functioning in Older Adults". The Investigators are seeking your consent to participate in research investigating the development of a mobile application that enhances physical and cognitive assessments. This is in response to the growing significance of the Short Physical Performance Battery (SPPB) in Alzheimer's Disease and R...
What is the current status of trial NCT06489847?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-08-01. Estimated completion is 2028-10-30.
What conditions does trial NCT06489847 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06489847?
The interventions under investigation include: SPPB++ Application (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06489847?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06489847 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06489847's enrollment target sits among peer trials
30 239th of 306 higher than 56 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI